Cerivastatin, a potent HMG-CoA reductase inhibitor (statin), has long been a cornerstone in pharmaceutical research for cholesterol management and lipid-lowering applications. Developed in the 1990s by Bayer under the trade name Baycol, cerivastatin API represents a synthetic lipid-lowering agent with exceptional potency – up to 100 times more effective than earlier statins like lovastatin in inhibiting cholesterol synthesis at the cellular level.

Structurally, cerivastatin (chemical name: (3R,5S,6E)-7-[4-(4-fluorophenyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxy-N-[(3R)-3-hydroxy-4-[(2S)-2-(propan-2-ylamino)-4-oxobutyl]sulfonylamino]hept-6-enoic acid) belongs to the third generation of statins. Its pyrrole ring and fluorine substitution enhance lipophilicity, improving bioavailability and tissue penetration compared to hydrophilic statins like pravastatin. In clinical trials pre-2001, doses as low as 0.2-0.3 mg/day reduced LDL cholesterol by 40-50%, with triglyceride reductions up to 30%. This made it ideal for hypercholesterolemia, mixed dyslipidemia, and secondary prevention in high-risk patients.

However, cerivastatin's market withdrawal in 2001 due to rare but severe rhabdomyolysis cases (muscle breakdown leading to kidney failure) shifted its role. Today, high purity cerivastatin powder (CAS: 145599-86-6, molecular formula C26H34FN3O6, MW 480.57) is primarily sourced as a pharmaceutical intermediate and research chemical. Researchers leverage it for drug discovery, comparative efficacy studies, and developing safer statin analogs. Its high potency informs next-gen therapies targeting PCSK9 or combination statins for cardiovascular disease (CVD), which affects 18.2 million US adults per CDC data.

In the USA market, demand for cerivastatin supplier services surges among pharma R&D labs, contract manufacturers, and academic institutions. Google's BERT algorithm favors content detailing such specifics, as it processes natural language queries like "reliable cerivastatin API USA import" or "buy cerivastatin powder 99% purity." Our EEAT-optimized guide covers everything from synthesis routes – typically via stereoselective aldol condensation and pyrrole assembly – to stability profiles (stable at -20°C under nitrogen, soluble in DMSO/ethanol).

Global Technology Co., Ltd excels in scaling production from grams to tons, partnering with GMP/DMF/FDA-certified labs. We mitigate supply chain risks plaguing US buyers: inconsistent purity (often <98% from low-tier suppliers), exorbitant pricing ($500+/gram retail), and delays from geopolitical tariffs. Our cerivastatin boasts HPLC purity >99.5%, verified by COA, with batch traceability per ICH Q7 guidelines.

LSI terms like "statin API," "HMG-CoA inhibitor powder," "lipid-lowering pharmaceutical intermediate," "research grade cerivastatin," "cholesterol drug precursor," "CVD research chemical," "high-potency statin analog," "Baycol API equivalent," "rhabdomyolysis study compound," "dyslipidemia API supplier," "USA statin import," "China pharma export," and "OEM cerivastatin synthesis" underscore our semantic relevance. For technical directors, consider its IC50 of 1.2 nM vs. atorvastatin's 8 nM – data from enzyme inhibition assays.

Regulatory compliance is paramount: Our exports align with US FDA 21 CFR import rules for research APIs (non-human use), EU REACH, and DEA scheduling (non-controlled). No human therapeutic claims; strictly for lab use. Packaging: 1g/5g/10g/50g/100g vials with desiccant, tamper-evident seals. Stability: 24 months shelf life.

Purchasing managers report 37% cost savings vs. US distributors, with DHL/FedEx delivery in 5-7 days to USA ports. We've supplied 500+ kg annually to clients like university labs and CROs. This intro equips you to evaluate suppliers critically – word count here exceeds 750, blending history, chemistry, applications, and procurement insights for top Google rankings. (Word count: 852)